Stephen Rocamboli

Mr. Rocamboli is currently Chief Executive Officer of Perla Therapeutics, Inc., a company located in the greater Boston area, developing first-in-class antibody therapeutics for the treatment of cancer. Previously, Mr. Rocamboli served as Chief Business Officer, General Counsel, and Corporate Secretary of Candel Therapeutics, an immuno-oncology company based in Needham, Massachusetts, between April 2015 and May 2020 (CNDL). Between 2010 and April 2015, Mr. Rocamboli served as general partner of Integrin Partners, LLC, a consulting firm providing corporate development, strategic transaction advisory, and general counsel services to life science companies, investors, and entrepreneurs. Between 2010 and 2012, Mr. Rocamboli also served as a partner of Beijing International Group, an international affiliate of Integrin Partners. Between 2014 and 2015, Mr. Rocamboli also served as Special Counsel to Wyrick Robbins Yates & Ponton, LLP, focusing on life sciences transactions. Between 2008 and 2018, Mr. Rocamboli was a co-founder and served as President of Pear Tree Pharmaceuticals, until its sale to Daré Bioscience, Inc. (DARE). Prior to joining Pear Tree, Mr. Rocamboli spent nearly a decade as a senior executive of a New York, NY-based private FINRA/SEC member investment bank, venture capital firm, and affiliated hedge funds focused exclusively on biotechnology and specialty pharmaceuticals. Mr. Rocamboli held positions of increasing responsibility, with the last five years as Senior Managing Director and General Counsel of all business units.